AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1431691 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser applied to the apical surface of resected roots
Number of subjects: 60
Study 1431691 — intervention group
Group type: COMPARATOR
Intervention: Nonlased roots
Number of subjects: 60
Study 3859595 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclofenamate sodium 200 mg
Number of subjects: 205
Study 3859595 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclofenamate sodium 100 mg
Number of subjects: 205
Study 3859595 — intervention group
Group type: COMPARATOR
Intervention: Buffered aspirin
Number of subjects: 205
Study 3859595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study 31557429 — intervention group
Group type: EXPERIMENTAL
Intervention: Total hip arthroplasty
Number of subjects: 1495
Study 31557429 — intervention group
Group type: COMPARATOR
Intervention: Hemiarthroplasty
Number of subjects: 1495
Study 29800468 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy for insomnia (CBT-I)
Number of subjects: 72
Study 29800468 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy for insomnia plus positive mood strategies (CBT-I+)
Number of subjects: 72
Study 29800468 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation control group (PCG)
Number of subjects: 72
Study 27390111 — intervention group
Group type: EXPERIMENTAL
Intervention: Real attentional bias training (ABT)
Number of subjects: 41
Study 27390111 — intervention group
Group type: COMPARATOR
Intervention: Sham attentional bias training (ABT)
Number of subjects: 41
Study 25706772 — intervention group
Group type: EXPERIMENTAL
Intervention: Nigella sativa (NS) 2g daily for one year
Number of subjects: 114
Study 25706772 — intervention group
Group type: COMPARATOR
Intervention: Activated charcoal (placebo)
Number of subjects: 114
Study 23414791 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I (hs-TnI)
Number of subjects: 3623
Study 23414791 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T (hs-TnT)
Number of subjects: 3623
Study 20026488 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronan-based heparin-bonded circuits (Vision HFO-GBS, Gish, CA, USA)
Number of subjects: 90
Study 20026488 — intervention group
Group type: COMPARATOR
Intervention: Uncoated controls
Number of subjects: 90
Study 18558796 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Number of subjects: 16583
Study 18558796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16583
Study 15681624 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone gel 1% (5 g applied once a day)
Number of subjects: 18
Study 15681624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 12854797 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular overdentures retained by two implants
Number of subjects: 60
Study 12854797 — intervention group
Group type: COMPARATOR
Intervention: Conventional mandibular complete dentures
Number of subjects: 60
Study 10435208 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 0.1 mg/kg
Number of subjects: 20
Study 10435208 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 2.0 mg/kg
Number of subjects: 20
Study 10435208 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 0.5 mcg/kg (test dose)
Number of subjects: 20
Study 8627976 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary nicorandil (0.25, 0.50, 1.0 mg)
Number of subjects: 46
Study 8627976 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide dinitrate (ISDN; 1.0 mg)
Number of subjects: 46
Study 2077525 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone (intravenous)
Number of subjects: 10
Study 2077525 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone (oral)
Number of subjects: 10
Study 2077525 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (intravenous)
Number of subjects: 10
Study 2077525 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (oral)
Number of subjects: 10
Study 2077525 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 10
Study 2077525 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 10
Study 2077525 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine glucuronides
Number of subjects: 10
Study 6793182 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpropamide (single dose)
Number of subjects: 0
Study 6793182 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpropamide (two weeks treatment)
Number of subjects: 0
Study 6793182 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 0
Study 6793182 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpropamide (single tablet)
Number of subjects: 0
Study 6793182 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma chlorpropamide or alcohol concentrations
Number of subjects: 0
Study 31055958 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosmetpantotenate
Number of subjects: 82
Study 31055958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 27986648 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 253
Study 26656357 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 63
Study 26656357 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine
Number of subjects: 63
Study 23398127 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram treatment in premenopausal women taking hormonal contraceptives
Number of subjects: 1440
Study 23398127 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram treatment in postmenopausal women taking hormone therapy
Number of subjects: 1440
Study 23398127 — intervention group
Group type: COMPARATOR
Intervention: Citalopram treatment in premenopausal women not taking contraception/HT
Number of subjects: 1440
Study 23398127 — intervention group
Group type: COMPARATOR
Intervention: Citalopram treatment in postmenopausal women not taking contraception/HT
Number of subjects: 1440
Study 21385354 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% tenofovir gel
Number of subjects: 889
Study 19811373 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmentation therapy with exogenous α1-antitrypsin (α1-AT)
Number of subjects: 1509
Study 19811373 — intervention group
Group type: COMPARATOR
Intervention: Control regimen (not specified)
Number of subjects: 1509
Study 17066085 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 4 mg + Indapamide 1.25 mg
Number of subjects: 135
Study 17066085 — intervention group
Group type: COMPARATOR
Intervention: Placebo (substituted for Perindopril 4 mg + Indapamide 1.25 mg)
Number of subjects: 135
Study 14742402 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative autologous donation (PAD)
Number of subjects: 50
Study 14742402 — intervention group
Group type: COMPARATOR
Intervention: Cell salvage (CS)
Number of subjects: 50
Study 14742402 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PAD and CS
Number of subjects: 50
Study 11176201 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble fiber intake
Number of subjects: 0
Study 11176201 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-saturated fat diet with fiber sources
Number of subjects: 0
Study 9781918 — intervention group
Group type: EXPERIMENTAL
Intervention: Zatebradine
Number of subjects: 35
Study 9781918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 8080674 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron
Number of subjects: 102
Study 8080674 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide plus lorazepam
Number of subjects: 102
Study 2806927 — intervention group
Group type: EXPERIMENTAL
Intervention: levodopa administration
Number of subjects: 16
Study 2806927 — intervention group
Group type: COMPARATOR
Intervention: control experiments without levodopa administration
Number of subjects: 16
Study 335382 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerisone cream (diflucortolone valerate 0.1%)
Number of subjects: 30
Study 335382 — intervention group
Group type: COMPARATOR
Intervention: Fluocinolone-acetonide ointments
Number of subjects: 30
Study 30273002 — intervention group
Group type: EXPERIMENTAL
Intervention: Videogame intervention (Crazy Taxi), 60 sessions of 1 hour each over 3 months
Number of subjects: 0
Study 30273002 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized training program (PositScience InSight), 60 sessions of 1 hour each over 3 months
Number of subjects: 0
Study 30273002 — intervention group
Group type: COMPARATOR
Intervention: No training (usual care/no intervention)
Number of subjects: 0
Study 27861239 — intervention group
Group type: EXPERIMENTAL
Intervention: Community + individual interventions (Arm 4)
Number of subjects: 455
Study 27861239 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (Arm 1)
Number of subjects: 455
Study 27861239 — intervention group
Group type: COMPARATOR
Intervention: Community intervention alone (Arm 2)
Number of subjects: 455
Study 27861239 — intervention group
Group type: COMPARATOR
Intervention: Individual intervention alone (Arm 3)
Number of subjects: 455
Study 25452629 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable vacuum‐formed retainer (VFR) covering the palate and the maxillary anterior teeth from canine‐to‐canine and bonded canine‐to‐canine retainer in the lower arch (group V‐CTC)
Number of subjects: 49
Study 25452629 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxillary VFR combined with stripping of the lower anterior teeth (group V‐S)
Number of subjects: 49
Study 25452629 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefabricated positioner (group P)
Number of subjects: 49
Study 23867047 — intervention group
Group type: EXPERIMENTAL
Intervention: DEVS programme (intervention group)
Number of subjects: 1752
Study 23867047 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual drug education)
Number of subjects: 1752
Study 22475112 — intervention group
Group type: COMPARATOR
Intervention: Placebo arm
Number of subjects: 1778
Study 22475112 — intervention group
Group type: EXPERIMENTAL
Intervention: Blind trial
Number of subjects: 1778
Study 19265605 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trials (RCTs)
Number of subjects: 0
Study 19265605 — intervention group
Group type: COMPARATOR
Intervention: Observational studies
Number of subjects: 0
Study 19265605 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RCTs and observational studies
Number of subjects: 0
Study 17485709 — intervention group
Group type: EXPERIMENTAL
Intervention: Periareolar injection of radiotracer and blue dye
Number of subjects: 449
Study 17485709 — intervention group
Group type: COMPARATOR
Intervention: Peritumoral injection of radiotracer and blue dye
Number of subjects: 449
Study 17485709 — intervention group
Group type: EXPERIMENTAL
Intervention: Periareolar injection of blue dye and/or gamma probe
Number of subjects: 449
Study 17485709 — intervention group
Group type: COMPARATOR
Intervention: Peritumoral injection of blue dye and/or gamma probe
Number of subjects: 449
Study 17485709 — intervention group
Group type: EXPERIMENTAL
Intervention: Periareolar injection of blue dye
Number of subjects: 449
Study 17485709 — intervention group
Group type: COMPARATOR
Intervention: Peritumoral injection of blue dye
Number of subjects: 449
Study 17485709 — intervention group
Group type: EXPERIMENTAL
Intervention: Periareolar injection by probe
Number of subjects: 449
Study 17485709 — intervention group
Group type: COMPARATOR
Intervention: Peritumoral injection by probe
Number of subjects: 449
Study 17485709 — intervention group
Group type: EXPERIMENTAL
Intervention: Periareolar injection
Number of subjects: 449
Study 17485709 — intervention group
Group type: COMPARATOR
Intervention: Peritumoral injection
Number of subjects: 449
Study 15189916 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination (purified, trivalent, split-virus vaccine)
Number of subjects: 125
Study 15189916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 15189916 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 125
Study 15704358 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten (9 mg/kg, once daily for 5 days)
Number of subjects: 2099
Study 15704358 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V (50,000 IU/kg, divided in three doses for 10 days)
Number of subjects: 2099
Study 15704358 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten
Number of subjects: 2099
Study 15704358 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V
Number of subjects: 2099
Study 15704358 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten and Penicillin V
Number of subjects: 2099
Study 9826222 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-dependent diabetes mellitus (IDDM) subjects
Number of subjects: 130
Study 9826222 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-dependent diabetes mellitus (IDDM) subjects with normoalbuminuria
Number of subjects: 130
Study 7985162 — intervention group
Group type: EXPERIMENTAL
Intervention: Capoten treatment according to the chronosensitivity-adjusted regimen
Number of subjects: 29
Study 7985162 — intervention group
Group type: COMPARATOR
Intervention: Capoten treatment according to the conventional scheme
Number of subjects: 29
Study 2605079 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg
Number of subjects: 20
Study 2605079 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil 0.5 mg
Number of subjects: 20
Study 30911271 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose dexmedetomidine (0.5 μg/kg) combined with low-dose remifentanil infusion (1 ng/mL)
Number of subjects: 169
Study 30911271 — intervention group
Group type: COMPARATOR
Intervention: High-dose remifentanil infusion (2 ng/mL)
Number of subjects: 169
Study 29122953 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie diet (LCD; 1250 kcal/day) for 12 weeks
Number of subjects: 56
Study 29122953 — intervention group
Group type: COMPARATOR
Intervention: Very-low-calorie diet (VLCD; 500 kcal/day) for 5 weeks followed by a weight stable period of 4 weeks
Number of subjects: 56
Study 29122953 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in ACE activity during dietary intervention
Number of subjects: 56
Study 29122953 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in FFA concentrations during dietary intervention
Number of subjects: 56
Study 29122953 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in RBP4 concentrations during dietary intervention
Number of subjects: 56
Study 25387342 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification and goniosynechialysis (PEGS)
Number of subjects: 30
Study 25387342 — intervention group
Group type: COMPARATOR
Intervention: Phacoemulsification alone (PE)
Number of subjects: 30
Study 25387342 — intervention group
Group type: COMPARATOR
Intervention: Comparison of PEGS and PE
Number of subjects: 30
Study 23978169 — intervention group
Group type: EXPERIMENTAL
Intervention: Modular treatment (MATCH)
Number of subjects: 174
Study 23978169 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 174
Study 23978169 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 174
Study 21178605 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive low-dose epidural ketamine (0.12% levobupivacaine, 2 μg/mL of fentanyl, 0.2 mg/mL ketamine, total volume of 500 mL)
Number of subjects: 133
Study 21178605 — intervention group
Group type: COMPARATOR
Intervention: Preemptive thoracic epidural analgesia without ketamine (0.12% levobupivacaine, 2 μg/mL of fentanyl, total volume of 500 mL)
Number of subjects: 133
Study 21178605 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive low-dose epidural ketamine
Number of subjects: 133
Study 21178605 — intervention group
Group type: COMPARATOR
Intervention: Preemptive thoracic epidural analgesia without ketamine
Number of subjects: 133
Study 18155054 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream (lidocaine 2.5% and prilocaine 2.5%), approximately 5 g
Number of subjects: 30
Study 18155054 — intervention group
Group type: COMPARATOR
Intervention: Control group (neomycin ointment, approximately 5 g)
Number of subjects: 30
Study 16926693 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management model
Number of subjects: 0
Study 16926693 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 12603175 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac (75mg twice daily)
Number of subjects: 24
Study 12603175 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (200mg twice daily)
Number of subjects: 24
Study 11137591 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics prescribed at discharge (amoxicillin clavulanate in 41%, amoxicillin in 15%, cefuroxime axetil in 11%, cefaclor 6%, azithromycin 5%)
Number of subjects: 821
Study 11137591 — intervention group
Group type: EXPERIMENTAL
Intervention: First choice antibiotics
Number of subjects: 821
Study 11137591 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate use antibiotics
Number of subjects: 821
Study 11137591 — intervention group
Group type: EXPERIMENTAL
Intervention: Inadequate treatment
Number of subjects: 821
Study 11137591 — intervention group
Group type: EXPERIMENTAL
Intervention: Variability in antibiotic prescription
Number of subjects: 821
Study 9205758 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebrotidine single doses (25 to 1600 mg)
Number of subjects: 16
Study 9205758 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebrotidine multiple doses (400 to 800 mg every 12 hours for 12 days)
Number of subjects: 16
Study 9205758 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebrotidine (single and multiple doses)
Number of subjects: 16
Study 7810458 — intervention group
Group type: EXPERIMENTAL
Intervention: Mainstreamed students
Number of subjects: 0
Study 7810458 — intervention group
Group type: COMPARATOR
Intervention: Other program placements
Number of subjects: 0
Study 7810458 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional-behavioral functioning
Number of subjects: 0
Study 7810458 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite score of the emotional-behavioral scale
Number of subjects: 0
Study 7810458 — intervention group
Group type: EXPERIMENTAL
Intervention: Level of functioning
Number of subjects: 0
Study 3076709 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine-sulfadoxine-pyrimethamine (MSP) at doses of 1, 1.5, or 2 standard MSP tablets (equivalent to 7.1-12.5 mg/kg mefloquine, 14.3-25.0 mg/kg sulfadoxine, 0.7-1.3 mg/kg pyrimethamine)
Number of subjects: 60
Study 30989073 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold diet
Number of subjects: 120
Study 28088798 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracranial‐B2LEED3S score derived from PERFORM trial
Number of subjects: 39432
Study 28088798 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk patients (score ≤2)
Number of subjects: 39432
Study 28088798 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk patients (score ≥5)
Number of subjects: 39432
Study 28088798 — intervention group
Group type: EXPERIMENTAL
Intervention: PERFORM trial
Number of subjects: 39432
Study 28088798 — intervention group
Group type: EXPERIMENTAL
Intervention: PRoFESS trial
Number of subjects: 39432
Study 25794622 — intervention group
Group type: EXPERIMENTAL
Intervention: TSHH (7.5 μg tiotropium/25 μg salmeterol, once daily)
Number of subjects: 50
Study 25794622 — intervention group
Group type: COMPARATOR
Intervention: TioHH (18 μg tiotropium, once daily)
Number of subjects: 50
Study 25794622 — intervention group
Group type: COMPARATOR
Intervention: SalD (50 μg salmeterol, twice daily)
Number of subjects: 50
Study 25794622 — intervention group
Group type: COMPARATOR
Intervention: Combination of TioHH (qd) plus SalD (bid)
Number of subjects: 50
Study 23945570 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular gentamicin once daily and oral amoxicillin twice daily for 7 days
Number of subjects: 750
Study 23945570 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular penicillin and gentamicin once daily for 2 days followed by oral amoxicillin twice daily for additional 5 days
Number of subjects: 750
Study 23945570 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular procaine-benzyl penicillin and gentamicin given once daily for 7 days
Number of subjects: 750
Study 21149658 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachytherapy (BT)
Number of subjects: 168
Study 21149658 — intervention group
Group type: COMPARATOR
Intervention: Radical Prostatectomy (RP)
Number of subjects: 168
Study 18272932 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (walking at 60% of maximal oxygen uptake for 90 min)
Number of subjects: 12
Study 18272932 — intervention group
Group type: COMPARATOR
Intervention: Control (resting)
Number of subjects: 12
Study 16517034 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP‐IPV‐Hib (Group 1)
Number of subjects: 241
Study 16517034 — intervention group
Group type: COMPARATOR
Intervention: DTwP/Hib+OPV (Group 2)
Number of subjects: 241
Study 14504951 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance measured at 50 kHz using Multiscan-5000 device.
Number of subjects: 96
Study 14504951 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous adipose tissue layers (SAT-layers) measured by LIPOMETER at various body sites.
Number of subjects: 96
Study 14504951 — intervention group
Group type: COMPARATOR
Intervention: Skinfold thicknesses measured by caliper.
Number of subjects: 96
Study 14504951 — intervention group
Group type: EXPERIMENTAL
Intervention: Iliac crest and front thigh skinfold thicknesses measured by caliper.
Number of subjects: 96
Study 14504951 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral thigh SAT-layer.
Number of subjects: 96
Study 14504951 — intervention group
Group type: EXPERIMENTAL
Intervention: Sum of skinfolds or SAT-layers.
Number of subjects: 96
Study 10744590 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut diet (replacing approximately 35% of energy from monounsaturated fat)
Number of subjects: 55
Study 10744590 — intervention group
Group type: COMPARATOR
Intervention: Mediterranean diet
Number of subjects: 55
Study 9095609 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1 infusion at 0.02 microgram.kg‐1.min‐1 before induction of anesthesia
Number of subjects: 109
Study 9095609 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PGE1)
Number of subjects: 109